Evidence map›Paper›PMID 32927769›Full record

ArticleCancers2020

Temozolomide-Induced RNA Interactome Uncovers Novel LncRNA Regulatory Loops in Glioblastoma.

Sabrina Fritah, Arnaud Muller, Wei Jiang, Ramkrishna Mitra, Mohamad Sarmini, Monika Dieterle, Anna Golebiewska, Tao Ye, Eric Van Dyck, Christel Herold-Mende and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Bioinformatic Tools for the Analysis and Prediction of ncRNA Interactions.International journal of molecular sciences · 2021
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 5 countries.

Sabrina FritahNORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
Arnaud MullerQuantitative Biology Unit, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
Wei JiangDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37203, USA.
Ramkrishna MitraDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37203, USA.
Mohamad SarminiNORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
Monika DieterleNORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
Anna GolebiewskaNORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.ORCID 0000-0002-4160-2521
Tao YeInstitut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique, UMR7104, Institut National de la Santé et de la Recherche Médicale, U964, Université de Strasbourg, 67404 Illkirch, France.ORCID 0000-0002-3394-2083
Eric Van DyckDNA Repair and Chemoresistance, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.
Christel Herold-MendeExperimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, 69120 Heidelberg, Germany.
Zhongming ZhaoDepartment of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37203, USA.ORCID 0000-0002-3477-0914
Francisco AzuajeNORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.ORCID 0000-0002-9207-9072
Simone P NiclouNORLUX Neuro-Oncology Laboratory, Department of Oncology, Luxembourg Institute of Health, Luxembourg L-1526, Luxembourg.ORCID 0000-0002-3417-9534
Luxembourg Institute of Health · LUVanderbilt University Medical Center · USHeidelberg University · DEInserm · FRUniversity of Luxembourg · LU

Funding

Fondation Cancer Luxembourg INCOMING
6 · The paper itself

Abstract

Resistance to chemotherapy by temozolomide (TMZ) is a major cause of glioblastoma (GBM) recurrence. So far, attempts to characterize factors that contribute to TMZ sensitivity have largely focused on protein-coding genes, and failed to provide effective therapeutic targets. Long noncoding RNAs (lncRNAs) are essential regulators of epigenetic-driven cell diversification, yet, their contribution to the transcriptional response to drugs is less understood. Here, we performed RNA-seq and small RNA-seq to provide a comprehensive map of transcriptome regulation upon TMZ in patient-derived GBM stem-like cells displaying different drug sensitivity. In a search for regulatory mechanisms, we integrated thousands of molecular associations stored in public databases to generate a background "RNA interactome". Our systems-level analysis uncovered a coordinated program of TMZ response reflected by regulatory circuits that involve transcription factors, mRNAs, miRNAs, and lncRNAs. We discovered 22 lncRNAs involved in regulatory loops and/or with functional relevance in drug response and prognostic value in gliomas. Thus, the investigation of TMZ-induced gene networks highlights novel RNA-based predictors of chemosensitivity in GBM. The computational modeling used to identify regulatory circuits underlying drug response and prioritizing gene candidates for functional validation is applicable to other datasets.

Indexed as

chemoresistanceglioblastomalncRNAregulatory circuittemozolomidetranscriptome

Identifiers

PMID32927769
PMCPMC7563839
OpenAlexW3083829023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.